The study population comprises patients with a first anterior myocardial infarction candidate for thrombolytic treatment, referred to emergency room of Shahid Madani Hospital,Tabriz.
In this double-blind study patients are randomized to two placebo and colchicines groups. Systematic randomization will be performed using computer-generated numbers by a nurse who was not involved in the treatment. The intervention group receives 2 mg of colchicines before thrombolytic treatment. Then colchicines will be given at 0.5 mg twice daily for 5 days. The patients in control group will receive the same dose of placebo. The subjects with the following condition will be excluded from our study:80 years old, history of allergy to colchicines or taking colchicines, receiving NSIADS, corticosteroids, patients diagnosed with inflammatory active diseases or cancer, renal failure, liver failure as well as the ones with carcinogenic shock, cardiac arrest or ventricular fibrillation, history of myocardial revascularization, thrombocytopenia and leucopenia. It should be noted that the initial and subsequent doses will depend on kidney and liver function test results (Bill, total, albumin, INR). Thus the subjects with kidney and liver failure will be excluded, too. Cardiac enzymes will be measured every 4-6 hours for 48 hours. Then the peak cardiac enzymes and their average will be measured. The left ventricular function will be quantified based on the echocardiography reports in the patients’ medical records performed by echocardiography physician. The cardiovascular events during hospitalization will be monitored and included in the study. Our checklist will include information on the basic variables, such as age, gender, infarction location, and coronary risk factors. Finally the participants in two groups will be compared in terms of enzyme infarct size, left ventricular systolic function and cardiovascular events during hospitalization.